<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:52:00 -0700</creation_date>
  <update_date>2013-05-27 11:06:42 -0600</update_date>
  <accession>HMDBP00845</accession>
  <secondary_accessions>
    <accession>6126</accession>
    <accession>HMDBP04418</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>GCS</synonym>
    <synonym>GLCT-1</synonym>
    <synonym>Glucosylceramide synthase</synonym>
    <synonym>UDP-glucose ceramide glucosyltransferase</synonym>
    <synonym>UDP-glucose:N-acylsphingosine D-glucosyltransferase</synonym>
  </synonyms>
  <gene_name>UGCG</gene_name>
  <general_function>Cell wall/membrane/envelope biogenesis</general_function>
  <specific_function>Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a "flippase".
</specific_function>
  <pathways>
    <pathway>
      <name>Sphingolipid Metabolism</name>
      <smpdb_id>SMP00034</smpdb_id>
      <kegg_map_id>map00500</kegg_map_id>
    </pathway>
    <pathway>
      <name>sphingolipid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00600</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00140</accession>
      <name>Glucosylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00286</accession>
      <name>Uridine diphosphate glucose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00295</accession>
      <name>Uridine 5'-diphosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04947</accession>
      <name>Ceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04948</accession>
      <name>Ceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04949</accession>
      <name>Ceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04950</accession>
      <name>Ceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04951</accession>
      <name>Ceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04952</accession>
      <name>Ceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04953</accession>
      <name>Cer(d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04954</accession>
      <name>Cer(d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04955</accession>
      <name>Cer(d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04956</accession>
      <name>Ceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04957</accession>
      <name>Ceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04969</accession>
      <name>Glucosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04970</accession>
      <name>Glucosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04971</accession>
      <name>Glucosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04972</accession>
      <name>Glucosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04973</accession>
      <name>Glucosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04974</accession>
      <name>Glucosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04975</accession>
      <name>Glucosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04976</accession>
      <name>Glucosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04977</accession>
      <name>Glucosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04979</accession>
      <name>Glucosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00790</accession>
      <name>N-Palmitoylsphingosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00829</accession>
      <name>N-Stearoylsphingosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00831</accession>
      <name>N-Lignoceroylsphingosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00950</accession>
      <name>Cer(d18:1/23:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06752</accession>
      <name>Dihydroceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10697</accession>
      <name>Cer(t18:0/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11758</accession>
      <name>Cer(d18:0/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11759</accession>
      <name>Cer(d18:0/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11760</accession>
      <name>Cer(d18:0/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11761</accession>
      <name>Cer(d18:0/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11762</accession>
      <name>Cer(d18:0/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11763</accession>
      <name>Cer(d18:0/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11764</accession>
      <name>Cer(d18:0/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11765</accession>
      <name>Cer(d18:0/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11766</accession>
      <name>Cer(d18:0/22:1(13Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11767</accession>
      <name>Cer(d18:0/23:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11768</accession>
      <name>Cer(d18:0/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11769</accession>
      <name>Cer(d18:0/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11770</accession>
      <name>Cer(d18:0/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11771</accession>
      <name>Cer(d18:0/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11772</accession>
      <name>Cer(d18:0/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11773</accession>
      <name>Cer(d18:1/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11774</accession>
      <name>Cer(d18:1/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11775</accession>
      <name>Cer(d18:1/22:1(13Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00024</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04832</accession>
      <name>Galabiosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04833</accession>
      <name>Galabiosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04834</accession>
      <name>Galabiosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04835</accession>
      <name>Galabiosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04836</accession>
      <name>Galabiosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04837</accession>
      <name>Galabiosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04838</accession>
      <name>Galabiosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04839</accession>
      <name>Galabiosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04840</accession>
      <name>Galabiosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04841</accession>
      <name>Galabiosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04866</accession>
      <name>Lactosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04872</accession>
      <name>Lactosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04873</accession>
      <name>Lactosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04874</accession>
      <name>Lactosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04876</accession>
      <name>Lactosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04877</accession>
      <name>Trihexosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04878</accession>
      <name>Trihexosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04879</accession>
      <name>Trihexosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04880</accession>
      <name>Trihexosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04881</accession>
      <name>Trihexosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04882</accession>
      <name>Trihexosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04883</accession>
      <name>Trihexosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04884</accession>
      <name>Trihexosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04886</accession>
      <name>Trihexosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04887</accession>
      <name>Trihexosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04958</accession>
      <name>Tetrahexosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04959</accession>
      <name>Tetrahexosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04960</accession>
      <name>Tetrahexosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04961</accession>
      <name>Tetrahexosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04962</accession>
      <name>Tetrahexosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04963</accession>
      <name>Tetrahexosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04964</accession>
      <name>Tetrahexosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04965</accession>
      <name>Tetrahexosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04966</accession>
      <name>Tetrahexosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04967</accession>
      <name>Tetrahexosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04968</accession>
      <name>Tetrahexosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04978</accession>
      <name>Glucosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06750</accession>
      <name>Lactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10708</accession>
      <name>Galactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10709</accession>
      <name>Galactosylceramide (d18:1/18:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10710</accession>
      <name>Galactosylceramide (d18:1/20:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10711</accession>
      <name>Galactosylceramide (d18:1/22:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10712</accession>
      <name>Galactosylceramide (d18:1/24:1(15Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10713</accession>
      <name>Galactosylceramide (d18:1/26:1(17Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10714</accession>
      <name>Galactosylceramide (d18:1/18:1(9Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB11591</accession>
      <name>Lactosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11592</accession>
      <name>Lactosyceramide (d18:1/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11594</accession>
      <name>Lactosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11595</accession>
      <name>Lactosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12237</accession>
      <name>Inositol-P-ceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12256</accession>
      <name>Mannosyl-diinositol-phosphorylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12257</accession>
      <name>Mannosyl-inositol-phosphorylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12311</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12312</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12313</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12314</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12315</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12316</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12317</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12318</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12319</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12320</accession>
      <name>Galactosylceramide (d18:1/12:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB12321</accession>
      <name>Galactosylceramide (d18:1/14:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB14563</accession>
      <name>Miglustat</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>Cellular component</category>
      <description>Golgi membrane</description>
      <go_id>GO:0000139</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>ceramide glucosyltransferase activity</description>
      <go_id>GO:0008120</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>epidermis development</description>
      <go_id>GO:0008544</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>glucosylceramide biosynthetic process</description>
      <go_id>GO:0006679</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>phospholipid metabolic process</description>
      <go_id>GO:0006644</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>9</chromosome_location>
    <locus>9q31</locus>
    <gene_sequence>&gt;1185 bp
ATGGCGCTGCTGGACCTGGCCTTGGAGGGAATGGCCGTCTTCGGGTTCGTCCTCTTCTTG
GTGCTGTGGCTGATGCATTTCATGGCTATCATCTACACCCGATTACACCTCAACAAGAAG
GCAACTGACAAACAGCCTTATAGCAAGCTCCCAGGTGTCTCTCTTCTGAAACCACTGAAA
GGGGTAGATCCTAACTTAATCAACAACCTGGAAACATTCTTTGAATTGGATTATCCCAAA
TATGAAGTGCTCCTTTGTGTACAAGATCATGATGATCCAGCCATTGATGTATGTAAGAAG
CTTCTTGGAAAATATCCAAATGTTGATGCTAGATTGTTTATAGGTGGTAAAAAAGTTGGC
ATTAATCCTAAAATTAATAATTTAATGCCAGGATATGAAGTTGCAAAGTATGATCTTATA
TGGATTTGTGATAGTGGAATAAGAGTAATTCCAGATACGCTTACTGACATGGTGAATCAA
ATGACAGAAAAAGTAGGCTTGGTTCACGGGCTGCCTTACGTAGCAGACAGACAGGGCTTT
GCTGCCACCTTAGAGCAGGTATATTTTGGAACTTCACATCCAAGATACTATATCTCTGCC
AATGTAACTGGTTTCAAATGTGTGACAGGAATGTCTTGTTTAATGAGAAAAGATGTGTTG
GATCAAGCAGGAGGACTTATAGCTTTTGCTCAGTACATTGCCGAAGATTACTTTATGGCC
AAAGCGATAGCTGACCGAGGTTGGAGGTTTGCAATGTCCACTCAAGTTGCAATGCAAAAC
TCTGGCTCATATTCAATTTCTCAGTTTCAATCCAGAATGATCAGGTGGACCAAACTACGA
ATTAACATGCTTCCTGCTACAATAATTTGTGAGCCAATTTCAGAATGCTTTGTTGCCAGT
TTAATTATTGGATGGGCAGCCCACCATGTGTTCAGATGGGATATTATGGTATTTTTCATG
TGTCATTGCCTGGCATGGTTTATATTTGACTACATTCAACTCAGGGGTGTCCAGGGTGGC
ACACTGTGTTTTTCAAAACTTGATTATGCAGTCGCCTGGTTCATCCGCGAATCCATGACA
ATATACATTTTTTTGTCTGCATTATGGGACCCAACTATAAGCTGGAGAACTGGTCGCTAC
AGATTACGCTGTGGGGGTACAGCAGAGGAAATCCTAGATGTATAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>394</residue_number>
    <molecular_weight>44853.255</molecular_weight>
    <theoretical_pi>7.789</theoretical_pi>
    <pfams>
      <pfam>
        <name>Glycos_transf_2</name>
        <pfam_id>PF00535</pfam_id>
      </pfam>
      <pfam>
        <name>Glyco_transf_21</name>
        <pfam_id>PF13506</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Ceramide glucosyltransferase
MALLDLALEGMAVFGFVLFLVLWLMHFMAIIYTRLHLNKKATDKQPYSKLPGVSLLKPLK
GVDPNLINNLETFFELDYPKYEVLLCVQDHDDPAIDVCKKLLGKYPNVDARLFIGGKKVG
INPKINNLMPGYEVAKYDLIWICDSGIRVIPDTLTDMVNQMTEKVGLVHGLPYVADRQGF
AATLEQVYFGTSHPRYYISANVTGFKCVTGMSCLMRKDVLDQAGGLIAFAQYIAEDYFMA
KAIADRGWRFAMSTQVAMQNSGSYSISQFQSRMIRWTKLRINMLPATIICEPISECFVAS
LIIGWAAHHVFRWDIMVFFMCHCLAWFIFDYIQLRGVQGGTLCFSKLDYAVAWFIRESMT
IYIFLSALWDPTISWRTGRYRLRCGGTAEEILDV</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>Q16739</uniprot_id>
  <uniprot_name>CEGT_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>D50840</genbank_gene_id>
  <genecard_id>UGCG</genecard_id>
  <geneatlas_id>UGCG</geneatlas_id>
  <hgnc_id>HGNC:12524</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Ichikawa S, Sakiyama H, Suzuki G, Hidari KI, Hirabayashi Y: Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4638-43.</reference_text>
      <pubmed_id>8643456</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ichikawa S, Sakiyama H, Suzuki G, Hidari KI, Hirabayashi Y: Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12654.</reference_text>
      <pubmed_id>8901638</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, Andrews TD, Searle S, Hunt SE, Scott CE, Jones MC, Ainscough R, Almeida JP, Ambrose KD, Ashwell RI, Babbage AK, Babbage S, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beasley H, Beasley O, Bird CP, Bray-Allen S, Brown AJ, Brown JY, Burford D, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Chen Y, Clarke G, Clark SY, Clee CM, Clegg S, Collier RE, Corby N, Crosier M, Cummings AT, Davies J, Dhami P, Dunn M, Dutta I, Dyer LW, Earthrowl ME, Faulkner L, Fleming CJ, Frankish A, Frankland JA, French L, Fricker DG, Garner P, Garnett J, Ghori J, Gilbert JG, Glison C, Grafham DV, Gribble S, Griffiths C, Griffiths-Jones S, Grocock R, Guy J, Hall RE, Hammond S, Harley JL, Harrison ES, Hart EA, Heath PD, Henderson CD, Hopkins BL, Howard PJ, Howden PJ, Huckle E, Johnson C, Johnson D, Joy AA, Kay M, Keenan S, Kershaw JK, Kimberley AM, King A, Knights A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd C, Lloyd DM, Lovell J, Martin S, Mashreghi-Mohammadi M, Matthews L, McLaren S, McLay KE, McMurray A, Milne S, Nickerson T, Nisbett J, Nordsiek G, Pearce AV, Peck AI, Porter KM, Pandian R, Pelan S, Phillimore B, Povey S, Ramsey Y, Rand V, Scharfe M, Sehra HK, Shownkeen R, Sims SK, Skuce CD, Smith M, Steward CA, Swarbreck D, Sycamore N, Tester J, Thorpe A, Tracey A, Tromans A, Thomas DW, Wall M, Wallis JM, West AP, Whitehead SL, Willey DL, Williams SA, Wilming L, Wray PW, Young L, Ashurst JL, Coulson A, Blocker H, Durbin R, Sulston JE, Hubbard T, Jackson MJ, Bentley DR, Beck S, Rogers J, Dunham I: DNA sequence and analysis of human chromosome 9.  Nature. 2004 May 27;429(6990):369-74.</reference_text>
      <pubmed_id>15164053</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60.</reference_text>
        <pubmed_id>12803929</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9.</reference_text>
        <pubmed_id>16247743</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, Chen SJ, Hwu WL: Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007 Oct;30(5):826. Epub 2007 Jun 21.</reference_text>
        <pubmed_id>17603755</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Treiber A, Morand O, Clozel M: The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007 Mar;37(3):298-314.</reference_text>
        <pubmed_id>17624027</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Ficicioglu C: Review of miglustat for clinical management in Gaucher disease type 1.  Ther Clin Risk Manag. 2008 Apr;4(2):425-31.</reference_text>
        <pubmed_id>18728838</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18.</reference_text>
        <pubmed_id>19956552</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Pastores GM: Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov. 2006 Jan;1(1):77-82.</reference_text>
        <pubmed_id>18221193</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>McCormack PL, Goa KL: Miglustat.  Drugs. 2003;63(22):2427-34; discussion 2435-6.</reference_text>
        <pubmed_id>14609352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M: Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica. 2006 May;91(5):703-6. Epub 2006 Apr 19.</reference_text>
        <pubmed_id>16627252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miglustat</name>
        <accession>HMDB14563</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
